President Trump recently brought together some of the biggest names in technology, describing the White House gathering as an important meeting of executives driving what he called the U.S. “Golden Age.”
A year after Congress eliminated the federal EV tax credit, America’s electric vehicle market has become genuinely difficult to characterize in a single sentence. Sales briefly topped 11% of new-car purchases last September as shoppers raced the deadline, then slid hard once the
Conventionally, the skull has largely been known as a structure which forms a protective casing around the brain. However, a recent study conducted by a team at WashU Medicine has found structures similar to lymph nodes inside the bone marrow in the
Rezolve Ai (NASDAQ: RZLV) received Court approval for its proposed capital reduction, an important step toward implementing its previously announced share repurchase program of up to $300 million. The approval follows shareholder approval of the capital reduction, with the company
Disseminated on behalf of SuperQ Quantum Computing Inc. and may include paid advertisements.
Rezolve Ai (NASDAQ: RZLV) is hosting its Investor Day at Nasdaq MarketSite in New York City, where management will present the company strategy, market opportunity, commercial model, growth drivers and platform for agentic commerce. In conjunction with the event, Rezolve
Beeline Holdings (NASDAQ: BLNE) provided a preliminary update on third-quarter 2026 performance, expecting revenue to reach the second-highest quarterly level in company history and the highest since 2021, while achieving its highest margins to date. Beeline also expects its net
Datavault AI (NASDAQ: DVLT) appointed Christopher R. Hardt to its board of directors as an independent director, effective Oct. 3, 2026. Hardt, who was designated by NYIAX in connection with Datavault AI recently completed acquisition, previously served on the NYIAX
A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) has completed its acquisition of Hedia, an Israeli retail media company with fiscal 2025 audited revenue of approximately $20 million. The acquisition combines A2Z Cust2Mate smart cart technology, digital in-store retail media inventory, shopper
Kairos Pharma (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The analysis showed a statistically significant difference in progression-free survival, with
Disseminated on behalf of BTQ Technologies Corp. and may include paid advertisements.
This article has been disseminated on behalf of Silvercorp Metals and may include paid advertising.
Healthcare and diagnostics operators are facing consolidation pressure, reimbursement uncertainty and more selective sponsors all at once. In that environment, how a capital raise is structured can matter as much as the business behind it. Market Street Capital is a boutique capital
Disseminated on behalf of Lahontan Gold Corp. and may include paid advertising.
The price of copper declined as the week drew to a close amid rising crude oil prices and a strengthening dollar. These two headwinds exerted downward pressure on most industrial metals. On Thursday alone, LME copper lost 1% to sell
OpenAI has decided against releasing a new artificial intelligence system after internal testing revealed problems with how reliably and safely it could operate. The system, known as GPT-6.1 Astra, was designed to work more independently than a conventional chatbot, including browsing the
Surgeons can now identify a brain tumor’s genetic makeup before a patient even leaves the operating table, cutting what used to be an eight-week wait for diagnosis down to about two hours. The Brain Tumor Research Center of Excellence at the
Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. Participants can bring research questions, technical
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, provided additional details on its Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus “BDBV” outbreak and other Ebola viruses in the Democratic
Silynxcom (NYSE American: SYNX), a manufacturer and developer of ruggedized tactical communication and hearing-protection devices, as well as other gear and accessories, recently announced that it received two consecutive purchase orders from a leading global defense company, totalling around $400,000